Collegium Pharmaceutical (COLL) reported $188 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 29.4%. EPS of $1.68 for the same period compares to $1.62 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $180.38 million, representing a surprise of +4.23%. The company delivered an EPS surprise of +3.7%, with the consensus EPS estimate being $1.62.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total product revenues- Belbuca: $52.6 million versus the two-analyst average estimate of $54.94 million. The reported number represents a year-over-year change of +0.8%.
- Total product revenues- Xtampza ER: $52.61 million versus $48.28 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +18% change.
- Total product revenues- Jornay PM: $32.63 million versus the two-analyst average estimate of $32.23 million.
- Total product revenues- Nucynta: $46.45 million compared to the $43.31 million average estimate based on two analysts. The reported number represents a change of +4.4% year over year.
- Total product revenues- Symproic: $3.72 million versus $3.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.7% change.
View all Key Company Metrics for Collegium Pharmaceutical here>>>
Shares of Collegium Pharmaceutical have returned -8.1% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
